Long-term safety and efficacy of autologous platelet lysate drops for treatment of ocular GvHD

Bone Marrow Transplant. 2017 Jan;52(1):101-106. doi: 10.1038/bmt.2016.221. Epub 2016 Sep 5.


Current ocular GvHD (oGvHD) treatments are suboptimal. We investigated the safety and efficacy of long-term continuous treatment with autologous platelet lysate (PL) drops in patients with oGvHD Dry Eye Syndrome (DES) score 2-3 refractory to topical conventional therapy. Ophthalmic evaluation was performed at 6 month intervals. Symptoms were assessed using the Glaucoma Symptom Scale (GSS). Patients were defined 'responders' when showing a reduction at least one grade on National Institutes of Health Eye Score from baseline at the 6 month visit. Thirty-one patients were included, and 16 (51%) completed 36 months of follow-up (range 6.5-72.7). At 6 months all patients were classified as responders: median GSS symptom score decreased from 70 to 41 (33 at 36 months), median GSS function score reduced from 68 to 46 (33 at 36 months) (all P<0.001). Median Tear Break Up Time improved from 3 to 6 s after 6 months and was maintained over time. All signs improved at 6 and 36 months (clinical and statistical significance). No severe adverse events occurred. Long-term treatment with PL drops is secure and effective for oGvHD and can be an efficient therapy option from initial stages of oGvHD to prevent permanent ocular impairment and improving quality of life.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Blood Platelets / chemistry*
  • Dry Eye Syndromes / drug therapy*
  • Female
  • Follow-Up Studies
  • Graft vs Host Disease / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Ophthalmic Solutions / administration & dosage*
  • Ophthalmic Solutions / adverse effects
  • Ophthalmic Solutions / chemistry*
  • Prospective Studies
  • Quality of Life*


  • Ophthalmic Solutions